Zdrowie i gospodarka · 17/04/2009

FDA Releases Draft Guidance for Industry on Submitting Summary Bioequivalence Data for ANDAs

The FDA has made available a draft guidance to help pharmaceutical companies comply with new regulations requiring the submission of bioequivalence data for generic drug applications, which will become effective in 2009.